Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2013

View Archived Issues

Baxter and Coherus Biosciences to develop and commercialize biosimilar products

NIAID to expand funding for development of bicyclolide from Enanta

Kyowa Hakko Kirin and Ultragenyx collaborate on development of KRN-23

Arsanis raises funds for S. aureus program

Diaxonhit and Boehringer Ingelheim enter oncology target agreement

Treatment with CSL-112 leads to rapid removal of cholesterol from atherosclerotic plaques

Clinical comparison and evaluation of treatment dressings in skin graft donors

PV-10 induces systemic tumor-specific immune responses following intralesional injection

Treatment with herbal preparation STW-5-II prevents DSS-induced ulcerative colitis in vivo

Roche presents novel cathepsin S inhibitors

Researchers at Amgen design novel Na(v)1.7 channel blockers

Parkinson's UK provides grant to study PBT-434

SanBio completes enrollment in stem cell SB-623 trial

Addex Therapeutics reports additional preclinical data on dipraglurant

Amgen prepares new agents that inhibit the GCK-GCKR interaction

Navidea awarded additional grant for NAV-4694 beta-amyloid imaging agent

AstraZeneca begins phase III program for olaparib

BNO-1016 shows efficacy in patients with acute viral rhinosinusitis

Rockwell Medical reports findings from CRUISE-2 study of SFP

Syndax grants Eddingpharm Chinese rights to entinostat

Repligen receives milestone from Pfizer for spinal muscular atrophy program

Sanofi and Pozen sign U.S. commercialization agreement for PA-8140 and PA-32540

Neurodyn acquires Memogain from Galantos Pharma

Theravance reports topline results from phase IIb study of TD-4208 for COPD

Vedolizumab BLA for ulcerative colitis receives FDA priority review status

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...